Angiogenesis inhibitors: implications for combination with conventional therapies

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and malignancy.
• Targeting angiogenesis is a validated strategy in cancer therapy.
• Combining angiogenesis inhibitors with conventional treatments is a promising approach.

Purpose of the Study:

• To review recent advancements in combining antiangiogenic drugs with conventional cancer therapies.
• To examine strategies for optimizing combination therapy regimens.
• To highlight the need for biomarkers in antiangiogenic therapy.

Main Methods:

• Review of preclinical and clinical evidence on combination antiangiogenic therapy.
• Discussion of drugs targeting the VEGF/VEGFR pathway.
• Examination of treatment optimization and patient stratification strategies.

Main Results:

• Evidence supports the feasibility of combining angiogenesis inhibitors with chemotherapy.
• VEGF/VEGFR pathway inhibitors are central to current combination strategies.
• The development of reliable biomarkers is essential for personalized antiangiogenic treatment.

Conclusions:

• Combination therapy involving antiangiogenic drugs and conventional treatments offers a viable strategy for cancer management.
• Optimizing treatment regimens and selecting appropriate patient populations through biomarkers are key to maximizing efficacy.
• Further research into biomarkers is needed to guide patient selection and monitor treatment response.